GO
Loading...

Merck & Co Inc

More

  • merck_logo.jpg

    After the closing bell yesterday, Merck announced that it plans to get rid of 12-hundred or around 15 percent of its sales reps. Like Schering-Plough, the company is having to adjust to lower sales of its Vytorin and Zetia cholesterol drugs and on top of that the Food and Drug...

  • Merck Plans to Reduce US Sales Force by 1,200 Monday, 5 May 2008 | 4:58 PM ET

    Merck, whose earnings have been hurt by patent expirations and declining sales of its Vytorin cholesterol fighter, said Monday it will eliminate another 1,200 members of its U.S. sales force as part of a restructuring begun in late 2005.

  • Not Having Enough Money Is Painful—Literally Thursday, 1 May 2008 | 6:38 PM ET

    Financial pain and physical pain may be linked: A new study says people who make less money and work in blue-collar jobs are more prone to be in pain.

  • Former Merck CEO Prodding Industry On Drug Pricing Thursday, 1 May 2008 | 10:31 AM ET
    Dr. Vagelos

    I didn't post yesterday because I was in Philadelphia shooting a story for an upcoming episode of "The Business of Innovation" on CNBC. It's a piece about big pharma and we went to Philly to interview the still very busy former CEO of Merck (two CEOs ago), Dr. Roy Vagelos.

  • Sudden Death: Merck, Delta and More Wednesday, 30 Apr 2008 | 6:59 PM ET

    It's a booyah-free zone. There goes Swifty!

  • Merck Warned by FDA over Manufacturing Plant Wednesday, 30 Apr 2008 | 11:51 AM ET

    Merck says it has received a warning letter from the Food and Drug Administration over concerns at one of its major vaccine manufacturing plants.

  • Stocks Fall Ahead of Fed Tuesday, 29 Apr 2008 | 6:13 PM ET
    graphic_word_ofthe_street.jpg

    The markets dropped a bit as investors eagerly await Wednesday's rate decision. Find out what was moving in the Word on the Street.

  • Tech Gains Boost Nasdaq; Airlines Rise Tuesday, 29 Apr 2008 | 5:04 PM ET

    Stocks closed mixed in thin trading Tuesday as the tide turned in technology's favor. Airline stocks rose as oil prices receded. Merck skidded after an FDA rejection.

  • Stocks Turn Higher; Airlines Rise Tuesday, 29 Apr 2008 | 2:55 PM ET

    Stocks pushed higher Tuesday despite concerns about interest rates ahead of the Federal Reserve's decision. Merck skidded after an FDA rejection. Airline stocks rose as oil prices receded.

  • Merck Drags on Dow; Airline Stocks Rise Tuesday, 29 Apr 2008 | 2:44 PM ET

    Stocks declined Tuesday amid concerns about interest rates and a slide in consumer confidence. Merck dragged on the Dow industrials after the FDA rejected a key cholesterol drug.

  • Merck "Adapts" To Tredaptive Setback Tuesday, 29 Apr 2008 | 11:37 AM ET
    merck_HQ2.jpg

    Investors are finding no solace in Merck's reaffirmation that it'll still hit its earnings numbers this year. Instead they're punishing the stock after the company announced what everyone is calling a surprise and a significant setback.

  • Merck Shares Plunge as Cholesterol Drug Rejected Tuesday, 29 Apr 2008 | 11:20 AM ET
    Merck

    U.S. health regulators have rejected a new drug from Merck that was designed to raise the level of HDL, or "good" cholesterol, the company said, sending its shares plunging more than 10 percent.

  • Forget Fed Watch Monday, 28 Apr 2008 | 6:15 PM ET

    Wall Street’s on the edge of its seat ahead of Wednesday’s interest-rate announcement. You should be on the phone with your broker.

  • Regulatory "Risky Business" for Pharma & Biotech Monday, 28 Apr 2008 | 11:56 AM ET
    Risky Business

    It's a big day for pipeline progress...or not. Late Friday, Merck and Schering-Plough announced that the Food and Drug Administration won't approve their combo Claritin-Singulair combo pill for allergies.

  • The Week:  Trading By the Numbers Saturday, 26 Apr 2008 | 11:42 AM ET
    dice_stock_chart_200.jpg

    Earnings Season shifted into high gear, both corporate results and economic statistics were all over the proverbial map, and investors and traders found opportunities in some unlikely places.

  • Amgen: Is "A" For Anemia Or Acquisition? Friday, 25 Apr 2008 | 12:35 PM ET
    AMGEN

    The morning after Amgen reported its first quarter earnings my inbox runneth over with analyst research reports on the biotech behemoth. The company beat the Street by eight cents a share. But the focus remains on the anemia drug franchise.

  • Schering Plows Through Vytorin Firestorm Wednesday, 23 Apr 2008 | 12:57 PM ET
    schering_plough_earnings.jpg

    Schering-Plough beat the Street by a surprising 16 cents per share and the beaten-down shares are rallying. In an exclusive CNBC interview Wednesday morning, Chairman and CEO Fred Hassan explained how the company was able to blow away estimates...

  • Halftime Report: Da Bears Are Winning Tuesday, 22 Apr 2008 | 12:41 PM ET

    This halftime report is not brought to you by (pick your prescription drug). So, we're pretty much at the midway point of big pharma's earnings season and Goldman Sachs analyst James Kelly is sizing things up so far...

  • Stop Trading!: Apple's Next Big Thing Monday, 21 Apr 2008 | 3:19 PM ET

    The iPhone was big. This could be even bigger, Cramer says.

  • Pharma in Focus: Insiders Sound Off Monday, 21 Apr 2008 | 1:23 PM ET

    Merck and Eli Lilly reported earnings today, and CNBC asked the pharmaceutical companies’ chief executives and an analyst to discuss the results and the sector as a whole.